Literature DB >> 20379853

The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.

E S Nakou1, T D Filippatos, A P Agouridis, C Kostara, E T Bairaktari, M S Elisaf.   

Abstract

We investigated the factors influencing triglycerides (TG) reduction during ezetimibe, alone or combined with orlistat, administration. Eighty-six obese hypercholesterolemic subjects were prescribed a low-fat diet and were randomized to ezetimibe (E group), orlistat (O group), or both (OE group) for 6 months. Plasma TG and apolipoprotein (apo) C-III reduction was significantly greater in the combination group compared with monotherapy. Multivariate analysis showed that in E group apoC-III reduction and baseline TG levels were independently positively correlated, whereas baseline apoC-II levels were negatively correlated, with TG lowering. In OE group apoC-III reduction was the only independent contributor to TG reduction.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20379853     DOI： 10.1007/s11745-010-3409-0

Source DB:  PubMed          Journal:  Lipids        ISSN： 0024-4201            Impact factor:   1.880


  47 in total

Review 1.  Orlistat-associated adverse effects and drug interactions: a critical review.

Authors:  Theodosios D Filippatos; Christos S Derdemezis; Irene F Gazi; Eleni S Nakou; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

2.  Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes.

Authors:  N Gervaise; M A Garrigue; G Lasfargues; P Lecomte
Journal:  Diabetologia       Date:  2000-06       Impact factor: 10.122

3.  Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice.

Authors:  M C Jong; P C Rensen; V E Dahlmans; H van der Boom; T J van Berkel; L M Havekes
Journal:  J Lipid Res       Date:  2001-10       Impact factor: 5.922

4.  The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).

Authors:  Margarita Garcia-Calvo; JeanMarie Lisnock; Herbert G Bull; Brian E Hawes; Duane A Burnett; Matthew P Braun; James H Crona; Harry R Davis; Dennis C Dean; Patricia A Detmers; Michael P Graziano; Meredith Hughes; D Euan Macintyre; Anthony Ogawa; Kim A O'neill; Sai Prasad N Iyer; Diane E Shevell; Marsha M Smith; Yui S Tang; Amanda M Makarewicz; Feroze Ujjainwalla; Scott W Altmann; Kevin T Chapman; Nancy A Thornberry
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-31       Impact factor: 11.205

5.  Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women.

Authors:  Maria Luz Fernandez; Shiva Metghalchi; Sonia Vega-López; Karin Conde-Knape; Timothy G Lohman; Zaida R Cordero-Macintyre
Journal:  J Nutr Biochem       Date:  2004-12       Impact factor: 6.048

6.  Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein.

Authors:  R C Kowal; J Herz; K H Weisgraber; R W Mahley; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

7.  Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.

Authors:  D Masuda; Y Nakagawa-Toyama; K Nakatani; M Inagaki; K Tsubakio-Yamamoto; J C Sandoval; T Ohama; M Nishida; M Ishigami; S Yamashita
Journal:  Eur J Clin Invest       Date:  2009-05-27       Impact factor: 4.686

8.  The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.

Authors:  T D Filippatos; E N Liberopoulos; M Kostapanos; I F Gazi; E C Papavasiliou; D N Kiortsis; A D Tselepis; M S Elisaf
Journal:  Diabetes Obes Metab       Date:  2007-04-24       Impact factor: 6.577

9.  Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.

Authors:  G Baggio; E Manzato; C Gabelli; R Fellin; S Martini; G B Enzi; F Verlato; M R Baiocchi; D L Sprecher; M L Kashyap
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

10.  The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.

Authors:  E S Nakou; T D Filippatos; M Georgoula; D N Kiortsis; A D Tselepis; D P Mikhailidis; M S Elisaf
Journal:  Curr Med Res Opin       Date:  2008-05-29       Impact factor: 2.580
View more
  13 in total

1.  Clinical applications of advanced lipoprotein testing in diabetes mellitus.

Authors:  Danyaal S Moin; Anand Rohatgi
Journal:  Clin Lipidol       Date:  2011-08-01

2.  Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes.

Authors:  Theodosios D Filippatos; Evangelos C Rizos; Vasilios Tsimihodimos; Irene F Gazi; Alexandros D Tselepis; Moses S Elisaf
Journal:  Lipids       Date:  2013-04-02       Impact factor: 1.880

3.  Role of ezetimibe in non-alcoholic fatty liver disease.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Hepatol       Date:  2011-10-27

Review 4.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 5.  ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.

Authors:  Ioannis Akoumianakis; Evangelia Zvintzou; Kyriakos Kypreos; Theodosios D Filippatos
Journal:  Curr Atheroscler Rep       Date:  2021-03-10       Impact factor: 5.113

Review 6.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

7.  Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Hu Wang; Li Wang; Yujia Cheng; Zhiqing Xia; Yifeng Liao; Jiang Cao
Journal:  Biomed Rep       Date:  2018-05-22

Review 8.  Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.

Authors:  Tracey G Simon; Kathleen E Corey; Raymond T Chung; Robert Giugliano
Journal:  Dig Dis Sci       Date:  2016-10-06       Impact factor: 3.199

Review 9.  A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

Authors:  Theodosios D Filippatos
Journal:  Cardiovasc Drugs Ther       Date:  2012-06       Impact factor: 3.727

10.  Phytosterols protect against diet-induced hypertriglyceridemia in Syrian golden hamsters.

Authors:  Todd C Rideout; Vanu Ramprasath; John D Griffin; Richard W Browne; Scott V Harding; Peter J H Jones
Journal:  Lipids Health Dis       Date:  2014-01-06       Impact factor: 3.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.